Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120288 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01120288: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01120288 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01120288, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Background: \- A protein called HIF is believed to be involved both in forming cancers and helping them to grow after they are formed. EZN-2968 is a new type of cancer drug that goes into the cancer cell and switches off the production of the HIF protein. Researchers are interested in testing EZN-2968 in people who have liver cancer because studies have shown that this drug travels to the liver and stays there when the drug is given through a vein. Objectives: \- To determine the safety and effectiveness of EZN-2968 on liver cancer. Eligibility: \- Individuals 18 years of age and older who have been diagnosed with liver cancer that has not responded to standard treatments. Design: * Participants will have an initial screening visit with a physical examination, blood and urine tests, and imaging studies to assess tumor size. Tumor biopsies may also be taken for research purposes. * Participants will have an undefined number of 6-week treatment cycles of EZN-2968, given once a week for 3 weeks followed by 3 weeks without the drug. * During each cycle, participants will have additional blood tests and imaging scans to assess tumor response to treatment. * Cycles of treatment with EZN-2968 may continue until the treatment is not effective, illness requires participants to stop taking the study drug, or the participant chooses to withdraw from the study.
Interventions
- DRUG EZN-2968
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-04-29 |
| Est. Completion | 2013-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01120288
The ClinicalTrials.gov registry entry for NCT01120288 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EZN-2968 is the first listed.
NCT01120288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01120288 about?
NCT01120288 is a clinical study titled "A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases". Background: \- A protein called HIF is believed to be involved both in forming cancers and helping them to grow after they are formed. EZN-2968 is a new type of cancer drug that goes into the cancer cell and switches off the production of the HIF protein. Researchers are interested in testing EZN-2...
What is the current status of trial NCT01120288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-04-29. Estimated completion is 2013-09-24.
What interventions are being tested in trial NCT01120288?
The interventions under investigation include: EZN-2968 (DRUG).
Who is sponsoring clinical trial NCT01120288?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.